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Although mechanisms leading to brain-specific inflammation and T cell activation have been widely investigated, regulatory mechanisms of local innate immune cells in the brain are only poorly understood. In this study, to our knowledge we show for the first time that MHC class II 
D
uring pathological conditions such as CNS infections, brain ischemia, or neuroinflammatory diseases such as multiple sclerosis or experimental autoimmune encephalomyelitis (EAE), leukocytes are recruited into the CNS parenchyma (1), mediating destructive inflammatory processes (2) . Microglia, the immune sentinels of the brain, present the first line of immune defense in the CNS whenever there is injury or disease (3) . Under steady-state, CNS microglia display a low APC phenotype. In EAE experiments, activated microglia are present in demyelinating lesions and express molecules of APC function (MHC class II [MHC II], CD40, CD80, CD86) (4-6) necessary to interact with brain-invading CD4 + immune cells (7) . It is generally thought that Th1 and also Th17 cells, directed against myelin Ags, enter the brain were they re-encounter their Ags presented by microglia and/or perivascular macrophages and initiate a destructive inflammatory cascade (2) .
Activated resident microglia also accumulate in lesion sites of acute brain ischemia (8) and noninflammatory entorhinal cortex lesion (ECL) (9) . In case of ECL, which results in axonal degeneration, cell death, and massive release of myelin Ags, microglia are activated, increase in number (10), phagocytose neuronal debris, and present Ags in an MHC II-dependent way. Additionally, a certain number of myelin-specific lymphocytes expand in draining lymph nodes, invade regions of degeneration (9, 11) , and mediate secondary white matter damage (12) . However, traumatic ECL does not elicit autoimmune encephalomyelitis-like white matter damage. Thus, the initial expansion of myelin-specific Th1 cells in regions of degeneration are tightly regulated and kept under control, implying active maintenance of tolerance.
In the periphery, CD4 + regulatory T cells (Tregs) ensure immune homeostasis and maintain immunological self-tolerance (13) . Natural thymus-derived Foxp3 + Tregs and inducible Agspecific Foxp3 + Tregs secrete anti-inflammatory cytokines, for example, IL-10 and TGF-b, and they alter the activity of APCs (14) . The induction of Ag-specific tolerance is essential to control autoreactive effector T cells and thus prevent autoimmune diseases (15 
Materials and Methods
Mice C57BL6/J wild-type mice were purchased from Elevage Janvier. C57Bl6/JFoxp3 EGFP reporter mice were provided by B. Malissen (20) . TCR transgenic C57BL/6-Tg (Tcra2D2,Tcrb2D2)1Kuch/J mice, known as 2D2 mice, and MHC II-deficient mice (B6.129S2-H2 dlAb1-Ea /J) were purchased from The Jackson Laboratory. 2D2 mice, reactive to myelin oligodendrocyte glycoprotein (MOG) , were intercrossed with Foxp3 EGFP reporter mice (2D2.Foxp3 EGFP ). All mice were bred and maintained under specific pathogen-free conditions and all experiments were performed according to institutional guidelines with approval of the Ethical Review Board at the animal facility of Charité-University Medicine Berlin.
EAE immunization
One day before EAE immunization, female C57BL6/J mice received either 500,000 CD4 + CD25 + Tregs i.v. in 200 ml PBS or PBS alone. Mice were immunized s.c. in the flanks with 250 mg MOG peptide (MEVG-WYRSPFSRVVHLYRNGK, Pepceuticals) emulsified in CFA containing H37 Ra (BD Biosciences). Pertussis toxin (List Biological Laboratories) was administered (400 ng/mouse) i.p. on the day of immunization and day 2. Individual animals were observed for signs of EAE for up to 30 d and scored using the following scale: 0, no disease; 1, limp tail and/or hindlimb ataxia; 2, hindlimb paresis; 3, hindlimb paralysis; 4, hindlimb and forelimb paralysis; 5, death.
T cell suppression assay

SNARF-1-labeled 2D2 CD4
+ T cells were seeded at 3 3 10 5 cells/well in a 96-well plate in RPMI 1640 media (10% FCS, 1% penicillin/streptomycin, 0.5 mM 2-ME) together with irradiated splenic cells (APCs) from the same animals ( 
Foxp3
2 T cells or alone in DMEM containing 10 mg/ml MOG . Proliferation was then assessed by SNARF-1 dilution using a FACSCanto II analyzer (BD Biosciences) at day 5.
Primary microglia culture and T cell coculture assay
Mixed glial cell cultures were prepared from cerebral cortex of newborn (P0-2) C57BL6/J mice as described previously (21) . Cortices and brain stem were isolated and the blood vessels and meninges were carefully removed. Following dissection, the tissues were subjected to enzymatic dissociation (0.05% trypsin-EDTA [Invitrogen] and 25 mg/ml DNase I [Roche]), washed in FCS containing HBSS. and resuspended in DMEM (10% FCS, 1% penicillin/streptomycin, 0.5 mM 2-ME). Mixed glial cells were seeded into poly-D-lysine-coated flasks and grown at 37˚C and 5% CO 2 . After 10-12 d microglia were separated from the underlying astrocytic layer by gentle shaking of the flask. Cultures usually contained .95% microglial (CD11b + ) cells. For coculture experiments microglia were seeded in 96-well plates (8 3 10 4 cells/well) and stimulated with varying amounts of rIFN-g (PeproTech) for 24 h (low dose, 10 U/ml; high dose, 100 U/ml) and then pulsed with synthesized MOG 35- 
Cytokine and chemokine detection
The concentrations of IL-13, IL-23, IL-6, IL-10, IL-1a, MCP-1, IL-4, TNF-a, and IL-17 in coculture supernatants were determined with bead-based multiple analyte detection (FlowCytomix; Bender MedSystems) according to the manufacturer's instructions. GM-CSF and TGF-b concentrations were analyzed using a multiplex protein assay (Milliplex; Millipore).
Flow cytometry analysis
Cells were acquired using a FACSCanto II analyzer (Diva software) and postacquisition data analysis was carried out using FlowJo software (Tree Star). The following mAbs were used: CD11b (M1/70), CD25 (PC61), CD4 (RM4-5), MHC II (M5/114.15.2), Vb11 (RR3-15), and TCR b-chain (H57-597) from BD Biosciences. The following cell proliferation dyes were used: eFluor 670 (eBioscience) and SNARF-1 (Molecular Probes).
TaqMan PCR
Predeveloped TaqMan gene expression assays and TaqMan Fast Mastermix (Applied Biosystems) were used for amplification of mRNA transcripts of
, and Hprt (Mm01545399_m1). Hprt was used as housekeeping gene. The results for the relative gene expression were calculated using the 2 2ΔΔCt method. All amplification reactions were performed on an ABI Prism 7500 Fast real-time PCR System (Applied Biosystems).
Epigenetic
Genomic DNA was analyzed by Epiontis (Berlin, Germany) as previously described (22) . Genomic DNA was isolated from mgTregs using a DNeasy blood kit (Qiagen) following the manufacturer's protocol. For analyzing the degree of methylation of individual CpG motifs within the murine Foxp3 locus, two overlapping amplicons were selected. DNA methylation analysis was performed by bisulfite sequencing by Epiontis. Cells harvested for bisulfide sequencing from microglia cocultures and lymph nodes were enriched for CD4 
Statistical analysis
Results
CD4 + Foxp3 + Tregs are induced by microglia
We set up an in vitro microglia/CD4 + T cell coculture system mimicking different microglial activation states by using rIFN-g in combination with the neuronal Ag MOG. CD4 + T cells were isolated from 2D2 mice intercrossed with Foxp3 EGFP reporter mice (2D2.Foxp3 EGFP ), providing us with MOG-specific CD4 + cells that express GFP in Foxp3 + Tregs. We observed a differential effect of microglia activation on CD4 + T cell responses when stimulated with either low-dose IFN-g/MOG (10 U/ml/1 mg/ml) or high-dose IFN-g/MOG (100 U/ml/10 mg/ml). When interacting with low dose-primed microglia, CD4 + T cells preferentially differentiated into Foxp3 Exemplarily, mean x-fold increases 6 SEM of high dose-versus low dose-stimulated supernatants on day 2 were: IL-13, 24.2 6 2.5; IL-17, 11.74 6 3.8; IL-6, 3.96 6 0.7. IL-10 increase in low-dose versus high-dose supernatants was 3.66 6 1. of high-dose IFN-g/MOG-stimulated microglia cells, we could only recover 8500 Foxp3 + cells per well. Furthermore, in cocultures of unstimulated microglia cells or microglia cells, which were stimulated with either IFN-g or MOG alone, we did not detect an increase in Foxp3 + mgTregs. That elevated mgTreg frequencies were strictly dependent on low-dose pretreatment of both, MOG peptide and IFN-g, which was further proven by titrating MOG peptide concentrations in the presence of either low-or high-dose IFN-g (Supplemental Fig. 1A) .
Kinetic experiments in low dose-activated microglia/T cell cocultures revealed an increase of Foxp3 + Tregs starting on day 3 (Fig. 1C) . The frequency of Foxp3 + mgTregs in low-dose cocultures constantly increased during 7 d. In contrast, the population of CD25 + Foxp3 2 T cells increased on day 1 and started to decrease on day 4 (Fig. 1C) . Within that time frame, we determined levels of IL-13, IL-17, IL-6, IL-10, TNF-a, MCP-1, and IFN-g in coculture supernatants (Fig. 1D, Supplemental Fig. 1B) . Levels of IL-13, IL-17, and IL-6 were significantly elevated only in high dose-treated cocultures. Low-dose pretreatment inhibited permanent production of IL-17 and reduced IL-6 and IL-13 levels. TNF-a and MCP-1 concentrations were increased in high-and low-dose IFN-g/MOG cocultures. In contrast, only low-dose stimulation of microglia resulted in a strong increase in the production of anti-inflammatory IL-10, especially during the first 4 d of coculture. Notably, we could not detect IL-4, IL-1a, IL-12, GM-CSF, or IL-23. Thus, depending on the IFN-g-induced activation of microglia, CD4 + T cells were directed into a more regulatory or effector state. Next, we deter- Fig. 1F ). In contrast, high dose-stimulated microglia induced proliferation of Foxp3 2 and Foxp3 + cells to the same extent (Fig. 1F) + Tregs efficiently suppressed the proliferation of effector T cells in vitro up to a ratio of 1:50 ( Fig. 2A, 2B, upper panel) . In the control, Foxp3 
CD25
+ cells (effector T cells) from the same cultures did not inhibit responder T cell proliferation (Fig. 2B, lower panel) . We further purified microglia-induced, MOG-specific CD25 + Tregs from cocultures and as a control isolated natural Treg cells (nTregs) from MOG TCR transgenic animals and adoptively transferred them into C57BL6/J recipients (500,000 cells/mouse) 1 d before induction of active EAE (MOG ). Transfer of mgTregs resulted in a constantly reduced clinical disease severity (Fig. 2C) whereas transfer of MOG-specific nTregs showed no change in clinical scores when compared with PBS-treated mice (Fig. 2C) . Mortality rates were 37% for the PBS control group, 50% for the nTreg group, and 0% when mgTregs were transferred (Fig. 2C) . To investigate signs of stability of in vitro-generated mgTregs we analyzed the conserved CpG-rich Treg-specific demethylated region (23) from Tregs induced by microglia and compared them to CD4 + CD25 + nTregs. Treg-specific demethylated region demethylation in the pool of microglia-induced CD4 + CD25 + Tregs was comparable to that of thymus-derived CD4 + CD25 + nTregs (Fig. 2D) , indicating a stable Foxp3 expression. Taken together, these data demonstrate that microglia-induced Tregs are potentially stable and highly suppressive in vitro and in vivo.
Microglia-mediated Treg induction is MHC class II-dependent and Ag-specific
In the steady-state brain, microglia do not express MHC II, but rapidly upregulate MHC II in response to injuries or inflammation and to IFN-g exposition derived from brain-infiltrating-activated effector T cells or NK cells (24) . We detected a clear IFN-g dosedependent increase of MHC II expression of primary microglia cells, with a 3.5-fold higher increase in MHC II mRNA expression in high dose-stimulated microglia compared with low dose-stimulated microglia after 48 h treatment (Fig. 3A) 
CD4
+ cells; data are representative for n = 3 separate experiments, mean 6 SEM of 5.9 6 0.8%).
Treg-inducing microglia are MHC II + CD40 dim CD86 dim IL-10 + Tolerogenic DCs express a distinct pattern of costimulatory molecules, cytokines, and tolerogenic markers (25) . We therefore examined the expression of CD40, CD80, CD86, and inducible NO synthase in microglia 48 h after IFN-g/MOG pretreatments. Stimulation significantly increased CD40 (Fig. 4A) , CD86 (Fig.  4B) , and inducible NO synthase (Supplemental Fig. 2D ) in a dosedependent manner but had no effect on CD80 (Fig. 4B) . The detected differences in CD86 mRNA expression were further supported by data from FACS analysis. High dose-stimulated microglia cells showed a significantly higher increase of CD86 surface expression per cell in comparison with low dose-stimulated microglia cells (Supplemental Fig. 2A ). To investigate the functional impact of variable CD40 expression levels and CD40/ CD40L interaction during microglia/T cell cocultures, we performed neutralization experiments. We cocultured high doseactivated microglia with CD4 + T cells in the presence of a neutralizing anti-CD154 (CD40L) Ab. Indeed, blocking of CD40/CD40L interaction resulted in a marked decrease of CD25 + Foxp3 2 effector cells, but did not effect generation of CD25 + Foxp3 + cells (Fig. 4C ). These experiments demonstrate that high CD40 expression and CD40/CD40L interaction is important for T effector cell but not mgTreg generation during cocultures.
Interestingly, low-level stimulation enhanced IL-10 mRNA expression by microglia (Fig. 4D) , whereas high-dose IFN-g stimulation resulted in only a minor increase in IL-10 expression (Fig. 4D) . Because IL-10 is known to reduce Ag presentation via, for example, modulation of MHC II expression, we analyzed MHC II expression after combined treatment of high-dose IFN-g/MOG and different doses of IL-10 (Fig. 5A) . Increasing levels of IL-10 resulted in a dose-dependent suppression of MHC II expression on microglia. Notably, we found the combination of high-dose IFN-g/MOG and 2 ng/ml IL-10 corresponding to low-dose levels of MHC II expression (21.6%, Fig. 5A ). Additionally, we tested whether TGF-b signaling is important for microglia-mediated induction of Tregs. We analyzed supernatants of control-, low dose-, and high dose-treated microglia before T cell coculture after 48 h of stimulation for the presence of TGF-b protein by multiplex protein assay. We were able to detect TGF-b protein, but without statistical difference between unstimulated, low dose-, and high dose-treated microglia, suggesting that the secretion level of TGF-b was not affected by IFN-g/MOG stimulation (Supplemental Fig. 2C) . This was further supported by analysis of microglial TGF-b expression on mRNA level. In line with the protein level, we could not detect TGF-b expression differences between control, low-dose-, and high dose-stimulated microglia (data not shown).
To test whether there is a direct link between IL-10 production and the regulatory microglia phenotype inducing Tregs, we combined high-dose IFN-g/MOG and IL-10 (2 ng/ml) treatment before coculture. Surprisingly, this combination of high-dose IFN-g/ MOG and IL-10 pretreatment prevented the differentiation of effector T cells and strongly induced Foxp3 + Treg comparable to that of low-dose IFN-g/MOG stimulation (30.5%, Fig. 5B ). Kinetic analysis of high dose-compared with high dose plus IL-10 (2 ng/ml)-stimulated cocultures did also show IL-10-mediated suppression of effector T cells (Fig. 5C ) and coculture kinetics comparable to those of low-dose pretreatment (Figs. 1C,  5C ). Because addition of IL-10 to high dose-stimulated microglia did reverse the "high-dose" effect of effector T cell induction/ accumulation and led to high frequencies of Foxp3 + Tregs instead (Fig. 5B) , we wondered whether we could detect expression differences besides those of MHC II between high dose-and high dose plus IL-10-treated microglia (Supplemental Fig. 2E ). Although the regulation of the costimulatory molecules CD40, CD80, and CD86 was not significantly affected, there was a trend to lower CD40 transcription upon IL-10 addition. Furthermore, exogenous IL-10 resulted in a significant downregulation of the chemokine CXCL10 and IFN-g inducible NO synthase, which is in line with findings from other groups (26) (27) (28) .
Thus, IL-10 is crucial for the regulatory phenotype of microglia in an inflammatory environment such as high doses of IFN-g/MOG.
Collectively, these data demonstrate that dose-dependent activation of microglia leads to different phenotypes of microglia comparable to tolerogenic/inflammatory DCs or anti-inflammatory type II monocytes in the periphery.
Discussion
In this study, we identified MHC II + CD40 dim CD86 dim IL-10 + microglia cells as a potent inducer of Foxp3 + Tregs. The capacity of microglia to induce Tregs depends on the amount of IFN-g and cognate Ag used to stimulate microglia. High dose-stimulated microglia with high MHC II and costimulatory molecule expression induced predominantly effector T cells, whereas low dosestimulated microglia with low MHC II and costimulatory molecule expression induced preferentially Foxp3 + Tregs. We suggest a finetuned mechanism by which microglia activation is controlled by a threshold of local IFN-g danger signals and Ag load (Fig. 6) . Below that threshold, low IFN-g signals induce a regulatory microglia phenotype. Above that threshold, high IFN-g induces an inflammatory phenotype resulting in an effector T cell response.
We assume that particularly in weak inflammatory CNS injuries low IFN-g levels from the initial invasion of T and NK cells give rise to microglia with a regulatory phenotype. In these settings, newly recruited T cells, which require Ag recognition, would then encounter microglia directing them toward a regulatory phenotype. This might also explain the late and long-lasting accumulation of Tregs after experimental stroke (middle cerebral artery occlusion) as demonstrated by our group (29) (29) . In this study, we show that in vitro microglia have the potential to mediate de novo induction and proliferation of Foxp3 + Tregs. Therefore, subimmunogenic activation of microglia by low-level IFN-g could be a possible regulatory mechanism that limits the expansion of autoantigen-specific effector T cells in the CNS.
Such mechanisms could also explain why ECL brain injury, despite the presence of myelin-specific T cells in injured regions, does not lead to destructive autoimmunity (30) .
In the periphery, mature DCs are enhancing T cell immunity, whereas immature DCs are involved in the induction of peripheral T cell tolerance to self-Ag (31) or to alloantigens (32) . Immature DCs are characterized by low expression of MHC II and adhesion and costimulatory molecules, leading to differentiation of Tregs rather than T effector cells (33) . Other groups showed that type II monocytes have anti-inflammatory properties promoting either Th2 or Treg responses in the periphery (34) . In this study, to our knowledge we show for the first time that brain-resident microglial cells activated by low-dose IFN-g and Ag induce Ag-specific, Foxp3
+ Tregs in vitro (Fig. 1) , similar to type II monocytes. The regulatory potential of microglia-induced Tregs was validated using a proliferation assay in vitro (Fig. 2) . Moreover, diminished EAE severity after adoptive Treg transfer reflects the suppressive function of microglia-induced Tregs in vivo. The administration of mgTregs during priming did not delay onset or peak of disease, but significantly decreased disease severity and mortality rate, suggesting that mgTregs interfere with disease progression. Because Korn et al. (17) found that CNS-derived autoantigen-specific effector T cells isolated at the peak of disease cannot be suppressed in vivo and in vitro by either CNS-derived or peripheral Ag-specific Tregs, disease amelioration mediated by transfer of microglia-induced Treg might already take place in the periphery during priming of T effector cells (e.g., draining lymph nodes). Surprisingly, in our study nTregs isolated from naive MOG TCR transgenic animals failed to suppress EAE disease scores. This is in apparent contrast to findings of Kohm et al. (35) who reported significant protection from the development of clinical EAE in BL6/J mice when transferring CD4 + CD25 + nTregs fom WT animals (35) . However, the authors transferred 2 3 10 6 cells, a considerably greater number of cells than used in our experimental set-up (500,000 cells/mouse).
mgTregs are epigenetically in a stable state, comparable to that of nTregs. We demonstrate in this study that microglia molecules required for effective Ag presentation or costimulation are tightly regulated by IFN-g levels, leading to opposite T cell responses (Figs. 3, 4) . The primary sources of IFN-g in the inflamed brain are Th1 and NK cells, DCs, and macrophages, but it has also been shown that low levels of IFN-g can be produced by astrocytes, fibroblasts, cerebrovascular endothelial cells, and microglia itself in the healthy CNS (36) (37) (38) . Microglia-mediated Treg induction is cell-cell contact-dependent, Ag-specific (dependent on MHC II and cognate peptide), and requires intermediate levels of CD40 and CD86 on the microglia site. These findings are further supported by a study from Ponomarev et al. (39) showing two populations of MHC II-expressing microglia during the peak of EAE: CD45 high -activated microglia expressing also high levels of costimulatory CD40 and CD86, and resting CD45 low microglia expressing very low levels of CD40 and CD86. They speculated that low level-activated microglia downmodulate CNS inflammation by mediating tolerance. Also, our results support that reducing the degree of CD40/CD40L interaction in microglia/T cell cocultures effects T effector cell generation (Fig. 3C) .
Performing ECL surgery on rats, CD80 and CD86 regulation on microglia in response to mechanically induced axonal degeneration (ECL) was studied by the Bechmann et al. (9) . They showed that after ECL, myelin is presented in a MHC II/CD86 rather than in a MHC II/CD80 context, leading to potential autoimmunity (9). This is in line with our in vitro findings showing that the different IFN-g/MOG stimulations applied to microglial cells did not lead to changes in CD80 mRNA levels.
Moreover, our data suggest a crucial role of IL-10 in modulating distinct microglia phenotypes. The pretreatment with IL-10 rescues the Treg response in cocultures with inflammatory (high dose)-activated microglia (Fig. 5) . Because IL-10 is known to downregulate MHC II, CD86, and CD80 on APCs, this can explain the suppressive phenotype of intermediately activated microglia. Also in our experiments, addition of IL-10 could downregulate MHC II but also CXCL10 expression of high dose-stimulated microglia (Fig. 5B) . Interestingly, it has been shown that addition of IP-10 can promote T effector cell proliferation and cytokine production (40) .
Moreover, DCs exposed to IL-10 proved to be in a tolerogenic rather than an inflammatory phenotype (41) . Because inducible Tregs can be generated in the presence of TGF-b (42) and/or IL-2, we analyzed TGF-b and IL-2 expression on mRNA level and found neither TGF-b being regulated nor IL-2 being expressed in microglia. Additionally, we analyzed TGF-b protein levels after 48 h stimulation, but found no significant difference between control-, low dose-, and high dose-stimulated microglia (Supplemental Fig. 2C ). Because TGF-b levels were reported to increase in lesioned brains (43) and microglia are known to secrete TGF-b under pathological conditions (44) , the contribution of TGF-b cannot be ruled out, but it seems to be IFN-g-independent.
Consistent with other findings, we could further show that microglia-induced activation of T cells leads to a time-dependent plasticity reflected by a mixture of cytokines released (45) . Highdose cocultures resulted in a massive release of IL-17, IL-13, IL-6, and TNF-a (Fig. 1D, Supplemental Fig. 1B) , whereas low doseprimed microglia T cell cocultures showed only intermediate levels of IL-6 and TNF-a and very small amounts of IL-13 or IL-17. These finding are in line with other studies describing a suppressive role for IL-6 in TGF-b-induced Foxp3 + Treg induction, and moreover the induction of pathogenic Th17 cells instead (46, 47) .
Taken together, our results identify MHC II + CD40 dim CD86 dim IL-10 + microglia as a potential inducer of Tregs in vitro. The expression of the anti-inflammatory molecule IL-10 seems to be responsible for the immature/regulatory phenotype of the microglia. The response of microglia cells to different amounts of local IFN-g and Ag load results in a fine-tuned immune response and contributes to either microglia-induced effector T cell or mgTreg generation. Microglia, as inducible APCs, have the ability to balance between beneficial and inflammatory T cell responses depending on activation state and microenvironment. Our findings enhance the understanding of how microglia may contribute to the control of adaptive immune responses in the brain.
